Frederick Coston Beddingfield MD PhD
Assistant Clinical Professor, Dermatology, UCLA School of Medicine
Join to View Full Profile
200 Medical Plz# 450Los Angeles, CA 90095
Phone+1 310-825-0631
Fax+1 310-794-7005
Dr. Beddingfield is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1998 - 2001
Los Angeles County-Harbor-UCLA Medical CenterResidency, Emergency Medicine, 1991 - 1995
University of North Carolina at Chapel Hill School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1992 - 2026
CO State Medical License 1995 - 1999
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat Start of enrollment: 2008 Apr 01
- Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 Start of enrollment: 2008 Jan 01
- Patient Experience Study of Deoxycholic Acid Injection Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsEfficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE TrialsSteven H. Dayan, Joel Schlessinger, Kenneth Beer, Lisa Donofrio, Derek H. Jones
Aesthetic Surgery Journal. 2018-08-16 - 24 citationsManagement of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental FatJeffrey S. Dover, Jeffrey M. Kenkel, Alastair Carruthers, Paul F. Lizzul, Todd M. Gross
Dermatologic Surgery. 2016-11-01 - 40 citationsOverview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat.Steven H. Dayan, Shannon Humphrey, Derek H. Jones, Paul F. Lizzul, Todd M. Gross
Dermatologic Surgery. 2016-11-01
Press Mentions
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)November 30th, 2022- Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal HemoglobinuriaJuly 28th, 2022
- Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, ChinaFebruary 23rd, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
